Q-omics provides the consensus-scored COL6A6 profile across patient tissues and cancer cell-line models. COL6A6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, COL6A6 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, COL6A6 protein abundance shows 17,760 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where COL6A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL6A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL6A6 survival associations across molecular data types. COL6A6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL6A6 RNA expression–survival associations across cancer types. High COL6A6 expression shows unfavorable associations in KIRC and OV, but favorable associations in HNSC, UVM, BRCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for COL6A6 RNA expression.
This table summarizes COL6A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for COL6A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL6A6 shows lower tumor expression in LUAD, KIRC, LIHC, LUSC, KIRP and BRCA. The LUAD box plot shows higher COL6A6 RNA expression in normal versus tumor tissue (log2 FC = −2.898, t-test p < 0.001).
This table shows molecular features associated with COL6A6 in patient tissues and cancer cell lines. In patient samples, COL6A6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, COL6A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
